Highlights Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
2.87 ^USD	-4.97%		-3.37%	-26.03%

05-08	Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	CI
04-18	Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	05-08	CI
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-12	CI
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	01-23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	01-23	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-16	CI
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	12-06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	11-27	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	13/10/23	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	06/09/23	CI
Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial	07/08/23	CI
Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology	27/07/23	CI
Anixa Biosciences Reports Issuance of Canadian Patent for CAR-T Cancer Therapy Technology	11/07/23	MT
Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	14/06/23	CI
Anixa Biosciences, Inc. and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine	17/04/23	CI
Anixa Biosciences Receives Patent Allowance Notice For Breast Cancer Vaccine Technology	27/02/23	MT
Anixa Biosciences, Inc. Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology	27/02/23	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	04/01/23	CI
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine	08/12/22	CI
Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic	26/10/22	CI
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	09/09/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Highlights

Filters